An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab Versus Extreme Study Revgimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) As First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

  • Alamgeer, Muhammad (Primary Chief Investigator (PCI))
  • Day, Daphne (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date12/02/19 → 11/02/24